Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 oxodotreotide - RayzeBio

Next Previous
Drug Profile

Actinium-225 oxodotreotide - RayzeBio

Alternative Names: 225Ac-DOTATATE; Actinium (225Ac) oxodotreotide - RayzeBio; Actinium-225 Dotate - RayzeBio; RYZ-101

Latest Information Update: 01 Jun 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator RayzeBio
  • Developer Ohio State University Comprehensive Cancer Center; RayzeBio
  • Class Antineoplastics; Drug conjugates; Peptides; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastro-enteropancreatic neuroendocrine tumour
  • Phase I/II Meningioma; Triple negative breast cancer
  • No development reported Small cell lung cancer

Most Recent Events

  • 22 May 2026 Ohio State University re-initiates the phase I/II PRIMe-STAR trial in Meningioma (Recurrent, Second-line therapy or greater) in USA (IV) (NCT07150806)
  • 14 Apr 2026 Ohio State University suspends phase I/II PRIMe-STAR clinical trials in Meningioma (Recurrent, Second-line therapy or greater) in USA (IV) due to operational adjustments made by sponsor (NCT07150806)
  • 28 Nov 2025 No recent reports of development identified for phase-I development in Small-cell-lung-cancer(Combination therapy, Late-stage disease) in USA (IV, Infusion)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top